NCT00424385View on ClinicalTrials.gov

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Gleevec + Sorafenib

400 mg Sorafenib every day (QD) 300mg Gleevec QD

Trial Locations (2)

60068

Oncology Specialists, S.C, Park Ridge

60714

Oncology Specialists, S.C, Niles

All Listed Sponsors
lead

Oncology Specialists, S.C.

OTHER

NCT00424385 - Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) | Biotech Hunter | Biotech Hunter